Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.59 |
| ▸ | BCL2A1 | Q16548 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983996 | 0.96 | METAP2 (0.93) | METAP2MCL1BCL2A1 | |
| SCHEMBL3982503 | 0.95 | METAP2 (0.91) | METAP2MCL1BCL2A1 | |
| SCHEMBL3984242 | 0.92 | METAP2 (1.00) | METAP2MCL1BCL2A1KDM4EALDH1A1 | |
| SCHEMBL3979169 | 0.87 | METAP2 (1.00) | METAP2MCL1BCL2A1KDM4EALDH1A1 | |
| SCHEMBL23200377 | 0.86 | METAP2 (0.76) | METAP2MCL1KDM4EALDH1A1 | |
| SCHEMBL3988639 | 0.84 | METAP2 (0.76) | METAP2MCL1BCL2A1KDM4EALDH1A1 | |
| SCHEMBL23200374 | 0.82 | METAP2 (0.70) | METAP2MCL1KDM4EALDH1A1 | |
| SCHEMBL3981264 | 0.81 | METAP2 (0.75) | METAP2MCL1BCL2A1KDM4EALDH1A1 | |
| SCHEMBL1981780 | 0.81 | METAP2 (0.68) | METAP2KDM4EALDH1A1 | |
| SCHEMBL5597858 | 0.81 | METAP2 (0.68) | METAP2MCL1BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | claimed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885MCL1 1545/4885BCL2A1 1450/4885 |
| US-20040068012-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885MCL1 1545/4885BCL2A1 1450/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885MCL1 1545/4885BCL2A1 1450/4885 |
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | METAP2, METAP1, ACER2 | METAP2 1/4885MCL1 4588/4885BCL2A1 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.